AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7551999 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior resection with preoperative radiotherapy
Number of subjects: 1292
Study 7551999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 1292
Study 1685105 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC + ABMT
Number of subjects: 35
Study 1685105 — intervention group
Group type: COMPARATOR
Intervention: ABMT
Number of subjects: 35
Study 7126401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted from bedtime (Group A)
Number of subjects: 128
Study 7126401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed 6 hours before anaesthesia (Group B)
Number of subjects: 128
Study 7126401 — intervention group
Group type: COMPARATOR
Intervention: Outpatients (fasted from bedtime)
Number of subjects: 128
Study 31957838 — intervention group
Group type: EXPERIMENTAL
Intervention: shENO1 (sh1, sh2, sh3)
Number of subjects: 0
Study 31426808 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hospital attendance
Number of subjects: 1393
Study 31426808 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hospital attendance
Number of subjects: 1393
Study 31426808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary hospital attendance
Number of subjects: 1393
Study 30216229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-MIBI
Number of subjects: 129
Study 30216229 — intervention group
Group type: COMPARATOR
Intervention: Tc-DTPA
Number of subjects: 129
Study 30216229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-MDP
Number of subjects: 129
Study 26782685 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline kyphosis angle (mean 48°, SD 12)
Number of subjects: 3038
Study 26782685 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10° greater kyphosis before adjusting for prevalent fracture
Number of subjects: 3038
Study 26782685 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10° greater kyphosis after adjusting for prevalent fracture
Number of subjects: 3038
Study 25180608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven titration of BIAsp 30
Number of subjects: 0
Study 25180608 — intervention group
Group type: COMPARATOR
Intervention: Investigator-driven titration of BIAsp 30
Number of subjects: 0
Study 22288732 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg after 6 weeks, 1.8 mg after 12 weeks)
Number of subjects: 44
Study 22288732 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 44
Study 19192221 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg bd
Number of subjects: 333
Study 19192221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 17428108 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 0
Study 17428108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene
Number of subjects: 0
Study 17428108 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoalkaloid (BEC-5) cream
Number of subjects: 0
Study 17428108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 0
Study 17428108 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 0
Study 15826235 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical self-motion (treadmill walking)
Number of subjects: 8
Study 15826235 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical translation (passive transport)
Number of subjects: 8
Study 15826235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both biomechanical self-motion and physical translation (walking)
Number of subjects: 8
Study 12042428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7576 microg or 25,000 IU of retinol palmitate daily)
Number of subjects: 80
Study 12042428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 20 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 30 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 40 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 50 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 60 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 70 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: EXPERIMENTAL
Intervention: NXX-066 80 mg BID
Number of subjects: 56
Study 10210264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7886648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hayek oscillator at 30 oscillations/min
Number of subjects: 8
Study 7886648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hayek oscillator at 60 oscillations/min
Number of subjects: 8
Study 7886648 — intervention group
Group type: COMPARATOR
Intervention: Sham settings (control)
Number of subjects: 8
Study 7886648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hayek oscillator at higher spans of pressure
Number of subjects: 8
Study 31075759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl ghrelin (5 pmol/kg/min)
Number of subjects: 2
Study 31075759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl ghrelin (1 pmol/kg/min)
Number of subjects: 2
Study 28526482 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback (60 trials)
Number of subjects: 15
Study 28526482 — intervention group
Group type: EXPERIMENTAL
Intervention: Force feedback (60 trials)
Number of subjects: 15
Study 25153479 — intervention group
Group type: EXPERIMENTAL
Intervention: Levulose containing sweets
Number of subjects: 20
Study 25153479 — intervention group
Group type: COMPARATOR
Intervention: Sucrose containing sweets
Number of subjects: 20
Study 23507258 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG 1.5mg/kg/day on days 0-3 (Group 1, n=8)
Number of subjects: 17
Study 23507258 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG 3mg/kg on days 0 and 3 (Group 2, n=9)
Number of subjects: 17
Study 21486974 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (FDC) regimen (rifampicin, isoniazid, pyrazinamide, ethambutol)
Number of subjects: 1585
Study 21486974 — intervention group
Group type: COMPARATOR
Intervention: Separate drugs regimen
Number of subjects: 1585
Study 21486974 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (FDC) regimen
Number of subjects: 1585
Study 16500638 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue of snake (threatening stimulus)
Number of subjects: 0
Study 16500638 — intervention group
Group type: COMPARATOR
Intervention: Visual cue of flower or mushroom (non-threatening stimuli)
Number of subjects: 0
Study 16500638 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fear of snakes and spiders
Number of subjects: 0
Study 15618322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 8
Study 15618322 — intervention group
Group type: COMPARATOR
Intervention: Early follicular phase
Number of subjects: 8
Study 15618322 — intervention group
Group type: COMPARATOR
Intervention: Midluteal phase
Number of subjects: 8
Study 12097224 — intervention group
Group type: EXPERIMENTAL
Intervention: External inhibition of learned rules
Number of subjects: 24
Study 12097224 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased stimulus salience
Number of subjects: 24
Study 12097224 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 10980854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 10980854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus doxorubicin plus escalating doses of paclitaxel
Number of subjects: 0
Study 7481864 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus doxorubicin plus paclitaxel
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 0
Study 7481864 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with or without ifosfamide or dibromodulcitol
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with ifosfamide or dibromodulcitol plus paclitaxel
Number of subjects: 0
Study 7481864 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel given concomitantly with radiation
Number of subjects: 0
Study 2127008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2
Study 6290980 — intervention group
Group type: EXPERIMENTAL
Intervention: pirprofen 200 mg
Number of subjects: 108
Study 6290980 — intervention group
Group type: EXPERIMENTAL
Intervention: pirprofen 400 mg
Number of subjects: 108
Study 6290980 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen 150 mg
Number of subjects: 108
Study 6290980 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study 31832778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triglyceride (TG) infusion
Number of subjects: 21
Study 31832778 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 21
Study 28601268 — intervention group
Group type: EXPERIMENTAL
Intervention: Crotalidae polyvalent immune Fab (ovine) (FabAV) antivenom
Number of subjects: 74
Study 28601268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26733110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab added to methotrexate (add-on)
Number of subjects: 223
Study 26733110 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab switched from methotrexate (switch)
Number of subjects: 223
Study 24691771 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise program (twice a week for 3 months)
Number of subjects: 48
Study 24691771 — intervention group
Group type: COMPARATOR
Intervention: Usual life activities (control group)
Number of subjects: 48
Study 23168226 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted turbinoplasty
Number of subjects: 40
Study 23168226 — intervention group
Group type: COMPARATOR
Intervention: Diode laser assisted turbinoplasty
Number of subjects: 40
Study 19417225 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoupled crank system
Number of subjects: 14
Study 19417225 — intervention group
Group type: COMPARATOR
Intervention: Traditional crank system
Number of subjects: 14
Study 17650794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of prednisone and cyclophosphamide (CTX) plus Chinese medicine Langchuang Recipe after gamma‐globulin treatment
Number of subjects: 19
Study 17650794 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and CTX
Number of subjects: 19
Study 16270522 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (5‐fluorouracil, Doxorubicin, Cyclophosphamide)
Number of subjects: 688
Study 16270522 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5‐fluorouracil)
Number of subjects: 688
Study 12037371 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mmol/l sodium hexafluorosilicate‐calcium chloride‐based two‐solution fluoride rinse
Number of subjects: 0
Study 12037371 — intervention group
Group type: COMPARATOR
Intervention: 12 mmol/l sodium fluoride rinse
Number of subjects: 0
Study 10221723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 41
Study 10221723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 41
Study 7608262 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (Nal; 100 mg/day) during estradiol (E2) and progesterone (P) administration (Nal 1)
Number of subjects: 9
Study 7608262 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (Nal; 100 mg/day) during pulsatile GnRH administration (Nal 2)
Number of subjects: 9
Study 7608262 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile GnRH administration (10 micrograms/pulse, iv, every 90 min)
Number of subjects: 9
Study 2404488 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 24
Study 2404488 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 24
Study 2404488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% MK-927
Number of subjects: 24
Study 2404488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 714260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone with or without azathioprine
Number of subjects: 0
Study 714260 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine alone
Number of subjects: 0
Study 714260 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 714260 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0
Study 31266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 70
Study 31266608 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study 29426436 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel (Dermatix Ultra) applied to one scar for 2 months
Number of subjects: 12
Study 29426436 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the other scar for 2 months
Number of subjects: 12
Study 26945393 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (1-2 post-tetanic count, n=36)
Number of subjects: 72
Study 26945393 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (1-2 train-of-four response, n=36)
Number of subjects: 72
Study 26945393 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 72
Study 24508983 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation program
Number of subjects: 1809
Study 24508983 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling
Number of subjects: 1809
Study 24508983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive telephone counseling
Number of subjects: 1809
Study 24508983 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Number of subjects: 1809
Study 24508983 — intervention group
Group type: COMPARATOR
Intervention: Control group (Reactive telephone counseling)
Number of subjects: 1809
Study 23232151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 100
Study 23232151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20666748 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 86
Study 20666748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral condensation
Number of subjects: 86
Study 20666748 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 86
Study 20666748 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 86
Study 17404119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy
Number of subjects: 293
Study 17404119 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care
Number of subjects: 293
Study 16109116 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/d
Number of subjects: 734
Study 16109116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 12099124 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning module
Number of subjects: 53
Study 12099124 — intervention group
Group type: COMPARATOR
Intervention: Preventive care guideline (Control)
Number of subjects: 53
Study 10405234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg every 8 hours for 24 hours)
Number of subjects: 36
Study 10405234 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg every 8 hours for 24 hours)
Number of subjects: 36
Study 7575799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB)
Number of subjects: 28
Study 7575799 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 28
Study 7575799 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scoring system
Number of subjects: 28
Study 2180390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin 2 g X 4 on the day of operation
Number of subjects: 174
Study 2180390 — intervention group
Group type: COMPARATOR
Intervention: Methicillin 1 g X 4 on the day of operation
Number of subjects: 174
Study 7361966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed immunization reminder to parents
Number of subjects: 0
Study 7361966 — intervention group
Group type: COMPARATOR
Intervention: No mailed reminder (control group)
Number of subjects: 0
Study 31701610 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT)
Number of subjects: 257
Study 27329448 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib (selective Lp-PLA2 inhibitor)
Number of subjects: 14500
Study 27329448 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp-PLA2 activity (baseline measurement)
Number of subjects: 14500
Study 24995472 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone impressions
Number of subjects: 0
Study 24995472 — intervention group
Group type: COMPARATOR
Intervention: Alginate impressions
Number of subjects: 0
Study 22904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol/calcium
Number of subjects: 173
Study 22904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol/placebo
Number of subjects: 173
Study 22904178 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 173
Study 22904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/placebo
Number of subjects: 173
Study 20053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariva/Stonewall (smokeless tobacco lozenges)
Number of subjects: 31
Study 20053788 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 31
Study 18046523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 5344
Study 15817428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg loading dose followed by 0.18 mg/kg/h continuous infusion for 6 days)
Number of subjects: 24
Study 15817428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15817428 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH (Continuous Veno-Venous Hemofiltration)
Number of subjects: 24
Study 15817428 — intervention group
Group type: COMPARATOR
Intervention: No CVVH
Number of subjects: 24
Study 14569215 — intervention group
Group type: EXPERIMENTAL
Intervention: PulStar Function Recording and Analysis System (PulStarFRAS)
Number of subjects: 18
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen alone (gel)
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen alone (cream)
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent alone
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent applied before sunscreen (group 1)
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent applied before sunscreen (group 2)
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent applied after sunscreen (group 1)
Number of subjects: 8
Study 10906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent applied after sunscreen (group 2)
Number of subjects: 8
Study 10906641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sunscreen or insect repellent)
Number of subjects: 8
Study 8814740 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium ion therapy
Number of subjects: 426
Study 8814740 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I radioactive plaque therapy
Number of subjects: 426
Study 8814740 — intervention group
Group type: COMPARATOR
Intervention: Helium ion therapy and 125I brachytherapy
Number of subjects: 426
Study 1705488 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF (2 micrograms/kg per day for 14 consecutive days)
Number of subjects: 0
Study 1705488 — intervention group
Group type: COMPARATOR
Intervention: Control (no rG-CSF)
Number of subjects: 0
Study 6403413 — intervention group
Group type: COMPARATOR
Intervention: Hexamethylmelamine, Adriamycin, and cyclophosphamide (HAC)
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and cis-platinum
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumor diameter <2 cm
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumor diameter >2 cm
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic toxicity
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal toxicity
Number of subjects: 169
Study 6403413 — intervention group
Group type: EXPERIMENTAL
Intervention: Other toxicities
Number of subjects: 169
Study 31627889 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid group (HES solution 750 ml)
Number of subjects: 80
Study 31627889 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid group (LR solution 2825 ml)
Number of subjects: 80
Study 29430176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alpha 1 antitrypsin (AAT)
Number of subjects: 0